# US 2015/0149095 A1 · Multi-parameter diabetes risk evaluations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0149095 A1
- Document ID: US20150149095A1
- Status: Published application
- Kind: A1
- Application number: 14/405,852
- Filed: 2013-06-07
- Published: 2015-05-28
- Earliest claimed: 2012-06-08
- Assignees: LipoScience, Inc.
- Applicants: LipoScience, Inc.
- Inventors: James D. Otvos; Irina Y. Shalaurova; Dennis W. Bennett; Justyna E. Wolak-Dinsmore; Thomas M. O'Connell; Kelly Mercier
- Web page: https://patentgrep.com/patent/US20150149095A1

## CPC

- A61B 5/4842: {Monitoring progression or stage of a disease}
- A61B 5/055: involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
- A61B 5/7275: {Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor}
- G01N 24/08: by using nuclear magnetic resonance (G01N24/12 takes precedence)
- G01R 33/46: NMR spectroscopy
- G01R 33/465: applied to biological material, e.g. in vitro testing
- G06F 17/10: Complex mathematical operations {(function generation by table look-up G06F1/03; evaluation of elementary functions by calculation G06F7/544)}
- G16H 20/10: relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H 50/30: for calculating health indices; for individual health risk assessment
- G16H 50/50: for simulation or modelling of medical disorders
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G01R: MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES (indicating correct tuning of resonant circuits H03J3/12)
- G06F: ELECTRIC DIGITAL DATA PROCESSING (computer systems based on specific computational models G06N)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject.

## Claims

### Claim 1

A method of evaluating a subject's risk of developing type 2 diabetes, comprising:
programmatically calculating a diabetes risk index of a subject using at least one defined mathematical model of risk of developing type 2 diabetes that includes a measurement of at least one lipoprotein component and at least one of a measurement of (i) GlycA or GlycB or (ii) at least one branched chain amino acid, obtained from at least one in vitro biosample of the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein one or more of the at least one lipoprotein component forms a numerator, denominator or multiplication factor of at least one interaction parameter.

### Claim 3 (depends on 1)

The method of claim 1, wherein the defined mathematical model of risk comprises GlycA, wherein the at least one lipoprotein component comprises an interaction parameter defined by the measurement of GlycA multiplied by a concentration of a defined subpopulation of high density lipoprotein (HDL) particles.

### Claim 4 (depends on 1)

The method of claim 1, wherein the at least one lipoprotein component of the defined mathematical model of risk comprises a first interaction parameter of the measurement of GlycA multiplied by a concentration of a defined subpopulation of high density lipoprotein (HDL) particles and wherein the HDL subpopulation comprises only medium HDL particle subclasses with diameters between about 8.3 nm (average) to about 10.0 nm (average).

### Claim at position 5

5-6. (canceled)

### Claim 7 (depends on 1)

The method of claim 1, further comprising programmatically generating a report with a graph of risk of progression to type 2 diabetes in the future versus ranges of glucose levels with a visual indication of higher and lower risk values with respect to the calculated diabetes risk index for ease of identifying or understanding risk stratification for a particular glucose level.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The method of claim 1, wherein the at least one defined mathematical model of risk includes NMR derived measurements of GlycA and Valine and at least one interaction parameter comprising a high density lipoprotein (HDL) particle subpopulation.

### Claim at position 9

10-13. (canceled)

### Claim 14 (depends on 1)

The method of claim 1, wherein the defined mathematical risk model includes only NMR derived measurements of a respective subject's at least one in vitro blood plasma or serum biosample.

### Claim 15 (depends on 1)

The method of claim 1, further comprising, before the programmatic calculation,
placing the in vitro biosample of the subject in an NMR spectrometer;
obtaining at least one NMR spectrum of the biosample;
deconvolving the obtained at least one NMR spectrum; and
calculating NMR derived measurements of GlycA and a plurality of selected lipoprotein subclassess based on the deconvolved at least one NMR spectrum.

### Claim 16 (depends on 15)

The method of claim 15, further comprising calculating a measurement of Valine as one of or as the only branched chain amino acid.

### Claim at position 13

17-19. (canceled)

### Claim 20 (depends on 1)

The method of claim 1, wherein the at least one lipoprotein component comprises at least one interaction parameter that includes a concentration of a subpopulation of high density lipoprotein (HDL) particles as a multiplication factor or a numerator or denominator of a ratio.

### Claim at position 15

21-25. (canceled)

### Claim 26

A circuit configured to determine whether a patient is at-risk for developing type 2 diabetes and/or whether a patient has prediabetes, comprising:
at least one processor configured to electronically calculate a diabetes risk index based on at least one mathematical model of risk to convergence to type 2 diabetes that considers a measurement of at least one lipoprotein component and a measurement of either (i) at least one branched chain amino acid or GlycA or (ii) at least one branched chain amino acid and GlycA, from at least one in vitro biosample of the subject.

### Claim 27 (depends on 26)

The circuit of claim 26, wherein the diabetes risk index is a numerical score within a defined score range, and wherein the circuit is in communication with or is configured with an electronic analysis circuit in communication with a respective display of remote electronic devices configured to allow a user to enter (i) a glucose value, (ii) a glucose value and a diabetes risk index score, or (iii) a diabetes risk index score, and wherein the circuit is configured to use a corresponding glucose value and a diabetes risk index score of a patient to stratify a risk of developing type 2 diabetes in the future for patients having the same glucose value when the glucose value is in an intermediate risk range associated with when fasting plasma glucose levels are between 90-110 mg/dL, A1C % levels are between 5.7-6.4 or oral glucose tolerance levels are between 140-199 mg/dL.

### Claim 28 (depends on 26)

The circuit of claim 26, wherein the at least one mathematical model of risk includes an NMR derived measurement of GlycA along with an NMR measurement of Valine, with Valine as the at least one branched chain amino acid, and wherein the at least one lipoprotein component includes a least one interaction parameter comprising a concentration of a sub-population of high density lipoprotein (HDL) particles.

### Claim 29 (depends on 26)

The circuit of claim 26, wherein the defined mathematical model of risk comprises GlycA, and wherein the at least one lipoprotein component comprises an interaction parameter of a measurement of GlycA multiplied by concentration of a defined subpopulation of high density lipoprotein (HDL) particles.

### Claim 30

(canceled)

### Claim 31 (depends on 29)

The circuit of claim 29, wherein the defined HDL subpopulation includes only medium HDL particle subclasses with diameters between 8.3 nm (average) to about 10.0 nm (average).

### Claim at position 22

32-33. (canceled)

### Claim 34 (depends on 26)

The circuit of claim 26, wherein the at least one processor is configured to generate a diabetes risk index as a numerical score with a defined range with a scores at a high end of the scale representing increased risk, and wherein the at least one processor is configured to generate a report with a graph of risk of progression to type 2 diabetes in the future versus ranges of glucose levels and a comparative scale of risk associated with the diabetes risk index score.

### Claim 35 (depends on 34)

The circuit of claim 34, wherein the graph includes visual references of at least comparative low risk DRI scores associated with a first quartile, first quintile or first decile of DRI scores and high risk DRI scores associated with a fourth quartile, fifth quintile or 10th deciles of DRI scores based on a defined population to thereby allow for ease of identifying or understanding risk stratification.

### Claim at position 25

36-40. (canceled)

### Claim 41

A computer program product for evaluating in vitro patient biosamples, the computer program product comprising:
a non-transitory computer readable storage medium having computer readable program code embodied in the medium, the computer-readable program code comprising:
computer readable program code that provides at least one mathematical model of risk to progression to type 2 diabetes in the future, wherein the at least one mathematical model of risk to progression to type 2 diabetes includes a plurality of components, including at least one lipoprotein component, at least one inflammatory biomarker and at least one branched chain amino acid; and
computer readable program code that calculates a diabetes risk index associated with a patient's biosample based on the at least one mathematical model of a risk of developing type 2 diabetes,
wherein the defined mathematical model of risk comprises GlycA as the inflammatory biomarker, and wherein the at least one lipoprotein component includes an interaction parameter of a measurement of GlycA multiplied by a concentration of a defined subpopulation of high density lipoprotein (HDL) particles.

### Claim 42 (depends on 41)

The computer program product of claim 41, wherein the computer readable program code that provides the at least one mathematical model includes model components of NMR derived measurements of GlycA as the inflammatory marker and Valine as the at least one branched chain amino acid.

### Claim at position 28

43-45. (canceled)

### Claim 46 (depends on 44)

The computer program product of claim 44, wherein the defined HDL subpopulation includes only medium HDL particle subclasses with diameters between 8.3 nm (average) to about 10.0 nm (average).

### Claim at position 30

47-53. (canceled)

### Claim 54

A system, comprising:
an NMR spectrometer for acquiring at least one NMR spectrum of an in vitro biosample; and
at least one processor in communication with the NMR spectrometer, the at least one processor configured to determine, for a respective biosample using the acquired at least one NMR spectrum, a diabetes risk index score based on at least one defined mathematical model of risk to convergence to type 2 diabetes that includes GlycA, at least one interaction parameter comprising GlycA and at least one lipoprotein component, and at least one branched chain amino acid obtained from at least one in vitro biosample of the subject, and wherein the at least one lipoprotein component of the interaction parameter includes a concentration of a defined subpopulation of high density lipoprotein (HDL) particles.

### Claim at position 32

55-70. (canceled)

### Claim 71

An NMR system comprising:
a NMR spectrometer;
a flow probe in communication with the spectrometer; and
at least one processor in communication with the spectrometer configured to obtain (i) NMR signal of a defined GlycA fitting region of NMR spectra associated with GlycA of a blood plasma or serum specimen in the flow probe; (ii) NMR signal of a defined branched chain amino acid fitting region of NMR spectra associated with the specimen in the flow probe; and (iii) NMR signal of lipoprotein subclasses;
wherein the at least one processor is configured to calculate measurements of (i) GlycA, (ii) at least one branched chain amino acid and (iii) the lipoprotein subclasses using the NMR signals, and wherein the at least one processor is configured to calculate a diabetes risk index that uses the calculated measurements of GlycA, the at least one branched chain amino acid and some of the lipoprotein subclasses.

### Claim 72

(canceled)

### Claim 73 (depends on 71)

The system of claim 71, wherein the at least one interaction parameter includes a first interaction parameter defined by a measurement of GlycA multiplied by a concentration of a defined subpopulation of high density lipoprotein (HDL) particles.

### Claim 74

(canceled)

### Claim 75 (depends on 71)

The system of claim 71, wherein the at least one processor calculates a concentration of a defined HDL subpopulation using HDL subclasses for at least one interaction parameter, wherein the HDL subpopulation comprises only medium HDL particle subclasses with diameters between 8.3 nm (average) to about 10.0 nm (average).

### Claim 76

(canceled)

### Claim 77

A method of monitoring a patient to evaluate a therapy or to determine whether the patient is at-risk of developing type 2 diabetes, comprising:
programmatically evaluating a plurality of NMR derived measurements of selected lipoprotein subclasses and at least one of (i) at least one branched chain amino acid or GlycA or (ii) at least one branched chain amino acid and GlycA, of at least one patient in vitro biosample;
programmatically calculating a diabetes risk index of respective patients using the NMR derived, measurements; and
evaluating at least one of (i) whether the diabetes risk index is above a defined level of a population norm associated with increased risk of developing type 2 diabetes; and/or (ii) whether the diabetes risk index is increasing or decreasing over time to thereby evaluate change in risk status that may be in response to a therapy.
